SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from the $10 million reported in the same period last year. The growth was driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system, which reached 30 units during the quarter. Gross profit climbed 20% to $7.1 million, yielding a gross margin of 50.9%, while the company posted a net loss of $2.7 million, or $0.01 per diluted share, compared with a net loss of $0.3 million a year earlier.
For the first half of 2026, revenue surged 65.6% to $25 million, with SSi Mantra installations increasing 47.4% to 56 systems. As of June 30, the company held $13.6 million in cash and cash equivalents, maintained no long-term debt, and had a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company also reported 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries, underscoring its leadership in remote surgical capabilities.
Notably, SS Innovations recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's global reach and potential to expand access to surgical care. The company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027, and it believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for entering major markets and could significantly boost adoption.
The strong financial results and operational progress highlight the increasing demand for affordable robotic surgery solutions. SS Innovations' focus on cost-effective technology positions it to compete in emerging markets, where the need for advanced surgical care is growing. The company's expansion into telesurgery also addresses barriers to specialized care in remote areas, potentially revolutionizing how surgery is delivered globally.
Investors and industry analysts are closely watching SS Innovations' regulatory pathway and international expansion. The company's ability to secure FDA clearance and CE marking will be pivotal in unlocking new revenue streams and establishing a stronger foothold in developed markets. With a solid balance sheet and no long-term debt, SS Innovations appears well-positioned to capitalize on these opportunities.
For more details, visit the full press release here. The latest news and updates on SSII are available in the company's newsroom at https://ibn.fm/SSII.
